Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency

    loading  Checking for direct PDF access through Ovid

Abstract

Delays in acting on cardiovascular safety concerns of the osteoporosis drug strontium ranelate have placed patients at risk, argue Mark Bolland and Andrew Grey

Related Topics

    loading  Loading Related Articles